EsoCap
EsoCap AG is a Swiss clinical-stage biotechnology company developing a mucoadhesive film platform for localized treatment of esophageal diseases. Its lead product, ESO-101, targets eosinophilic esophagitis and completed a statistically significant Phase II trial.
- Company typePrivate
- Founded2017
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What EsoCap does
EsoCap AG is a Swiss clinical-stage biotechnology company founded in 2017 and headquartered in Basel. It develops therapies for patients with diseases of the esophagus, with its lead product, ESO-101, in development for eosinophilic esophagitis (EoE). The Phase II ACESO trial was reported as successful and statistically significant with p=0.0318, and ESO-101 received FDA Orphan Drug Designation.
The company's core technology is a swallowable application system that places a thin, degradable, drug-loaded mucoadhesive film directly on the esophageal mucosa. This design is intended to provide localized, sustained drug exposure in the upper gastrointestinal tract, where conventional oral and injectable therapies can have difficulty achieving sufficient local exposure. EsoCap also reports development work involving 3D-printed films, hot-melt-extrusion fiber production, and delivery of RNA and biologics, although no additional clinical-stage product is identified.
EsoCap is pre-revenue and has a reported team of 1–10 employees. Its disclosed network includes LTS Lohmann and Lonza for manufacturing, Zühlke Engineering for an automated assembly-line prototype, FGK Clinical Research, and the University of Greifswald, from which the underlying technology was licensed. The platform has patents granted in more than 13 jurisdictions and a CE-certified application device; the available data do not disclose commercial pricing, product sales, licensing income, or a finalized go-to-market model.
EsoCap firmographics
Firmographics- Name
- EsoCap
- Legal name
- EsoCap AG
- Website
- https://esocapbiotech.ch
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EsoCap AG is a Swiss clinical-stage biotechnology company developing a mucoadhesive film platform for localized treatment of esophageal diseases. Its lead product, ESO-101, targets eosinophilic esophagitis and completed a statistically significant Phase II trial.
- Ownership category
- akta.pro rank
Where EsoCap is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
EsoCap business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Licensing: Pre-revenue clinical-stage biotech pursuing licensing partnerships with pharmaceutical companies for commercialization of ESO-101 and the EsoCap platform technology. Revenue model will likely involve upfront payments, milestone payments, and royalties upon regulatory approval and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
EsoCap product offering
Product offeringCore offering
EsoCap develops a proprietary mucoadhesive film drug delivery platform packaged inside a swallowable capsule to enable targeted, long-lasting local therapy of the esophagus. The capsule deploys a thin, API-loaded film that adheres to the esophageal mucosa for 15+ minutes, allowing topical treatment of esophageal diseases for the first time. Its lead drug candidate, ESO-101, delivers mometasone furoate via this platform for once-daily treatment of eosinophilic esophagitis (EoE) and has successfully completed a Phase II trial (ACESO).
Product overview
EsoCap AG is a Swiss biotech company pioneering an innovative drug delivery platform for the world's first local treatment of the esophagus. The core offering consists of the EsoCap System, a platform technology that uses a capsule containing a thin mucoadhesive film to achieve targeted, long-lasting drug delivery to the esophageal mucosa. The lead product candidate, ESO-101, applies mometasone furoate via this platform for the treatment of eosinophilic esophagitis (EoE). The platform technology has demonstrated versatility by successfully incorporating small molecules, peptides, antibodies, and liposomal encapsulated RNA. The completed ACESO Phase II clinical trial validated the safety and efficacy of ESO-101, with results published in Alimentary Pharmacology & Therapeutics.
Differentiator
Problem solved
Functional benefit
Products and services
- ESO-101
Quantifiable outcome
- Statistically significant reduction in peak eosinophil count (p=0.0318) compared to placebo in Phase II ACESO trial
- +2 more outcomes
Companies that use EsoCap
Customer profileSegments2 records
Ideal customer profiles2 records
EsoCap technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
EsoCap partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered supporting and core.
- Zühlke EngineeringsupportingDeveloped prototype automated assembly line for EsoCap's manufacturing process. Zühlke engineers used virtual reality (VR) and 3D printing technologies to efficiently develop a production line capable of manufacturing millions of EsoCaps per year.
- FGK CROsupportingContract Research Organization that partnered with EsoCap for the ACESO Phase II clinical trial, providing clinical operations support across 14 clinics in 5 European countries.
- Hänggli Thermoplast AGsupportingManufacturer of injection-molded plastic elements for EsoCap's application device. Successfully fulfilled obligations towards Swissmedic and EU requirements for medical device production.
- LTS Lohmann Therapy-Systeme AGcoreIndustrial development collaboration for manufacturing clinical trial samples. LTS is a leading pharmaceutical technology company developing and manufacturing innovative thin film drug delivery systems with over 20 marketed products and 30+ pipeline projects. Collaboration leverages LTS's thin film expertise with EsoCap's innovative application technology.
- University of GreifswaldcoreExclusive worldwide licensing agreement for the unique drug delivery technology developed by Prof. Werner Weitschies and his team at the Center of Drug Absorption and Transport. The university developed the core EsoCap technology including the mucoadhesive film system and EsoPeriDiss release model. Ongoing collaboration on research including 3D-printed films, hot-melt extrusion, and RNA drug delivery development.
- LonzasupportingLonza's Capsules & Health Ingredients business provides innovative capsule solutions and dosage form expertise. Lonza serves over 5,000 customers in 100+ countries and brings capsule polymer science expertise for optimizing bioavailability and targeted delivery.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
EsoCap competitors and assessment
Company assessmentEmerging players
- BioDelivery Sciences International: Specialty pharmaceutical company with proprietary drug delivery technologies (including buccal film technology). Comparable in its focus on novel drug delivery platforms to enable localized drug administration.
- Ellodi Pharmaceuticals: EoE-focused biotech developing targeted therapies for eosinophilic esophagitis. Comparable to EsoCap in indication focus and stage, though with different therapeutic modalities.
- Phathom Pharmaceuticals: GI-focused specialty pharmaceutical company developing treatments for gastric acid-related disorders. Comparable in its focus on underserved GI conditions and specialty pharma commercial model.
- RedHill Biopharma: Specialty biopharmaceutical company focused on gastrointestinal diseases. Comparable in its GI therapeutic focus and commercialization model for underserved GI conditions.
Broad incumbents
- Takeda Pharmaceutical: Global pharmaceutical company with an approved EoE therapy (budesonide oral suspension) and established gastroenterology franchise. Represents the primary incumbent EsoCap would compete against in EoE.
- Sanofi / Regeneron: Biopharmaceutical companies with Dupixent (dupilumab) approved for EoE. A major incumbent competitor with established commercial infrastructure and physician relationships in the EoE market.
- Halozyme Therapeutics: Drug delivery platform company with proprietary ENHANZE technology for subcutaneous drug delivery. Comparable in its platform-based drug delivery approach and licensing/royalty business model.
- Ironwood Pharmaceuticals: GI-focused pharmaceutical company with commercial-stage products in gastrointestinal disorders. Comparable in its GI therapeutic focus and specialty pharma commercial approach.
Direct peers
- Allakos: Clinical-stage biopharmaceutical company developing therapeutics for eosinophilic gastrointestinal diseases including EoE. A direct comparable in terms of indication focus and clinical-stage biotech profile.
- Adare Pharmaceuticals: Specialty pharmaceutical company focused on EoE and GI drug delivery, with an approved EoE therapy (budesonide oral suspension). Highly comparable to EsoCap given shared EoE focus and emphasis on localized/topical GI delivery.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
EsoCap social profiles
Digital presenceEsoCap compliance and trust
Trust signalCompliance3 records
EsoCap financial estimates
Financial estimateRevenue estimate
Valuation estimate
EsoCap leadership team
Management profileNumber of profiles
Profiles6 records
EsoCap funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EsoCap M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EsoCap
What does EsoCap do?
EsoCap develops a proprietary mucoadhesive film drug delivery platform packaged inside a swallowable capsule to enable targeted, long-lasting local therapy of the esophagus. The capsule deploys a thin, API-loaded film that adheres to the esophageal mucosa for 15+ minutes, allowing topical treatment of esophageal diseases for the first time. Its lead drug candidate, ESO-101, delivers mometasone furoate via this platform for once-daily treatment of eosinophilic esophagitis (EoE) and has successfully completed a Phase II trial (ACESO).
Is EsoCap a public or private company?
EsoCap is a private company. It is classified as venture growth investor backed and is currently operating.
When was EsoCap founded?
EsoCap was founded in 2017. It employs 1 to 10 people.
Where is EsoCap based?
EsoCap is headquartered in Basel, Switzerland, in the Europe region.
How does EsoCap make money?
One revenue line is on record: pharmaceutical Product Licensing.
Who are EsoCap's main competitors?
Emerging players on record are BioDelivery Sciences International, Ellodi Pharmaceuticals, Phathom Pharmaceuticals and RedHill Biopharma. Broad incumbents are Takeda Pharmaceutical, Sanofi / Regeneron, Halozyme Therapeutics and Ironwood Pharmaceuticals. Direct peers are Allakos and Adare Pharmaceuticals.
Does EsoCap have an API?
No public API is recorded for EsoCap.